Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
about
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapyOral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic reviewMarine Diterpenoids as Potential Anti-Inflammatory AgentsCyclooxygenase-2 in epilepsy.Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outsCOX-2 and cancer: a new approach to an old problemA three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitorsEffects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challengePharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbitsSubstance P, opioid, and catecholamine systems in the mouse central nervous system (CNS).Effects of soy diet on inflammation-induced primary and secondary hyperalgesia in ratCyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectivesCyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury.LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expressionCyclooxygenase-2 inhibitors: promise or peril?Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors.Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritisPreclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.Accelerated fracture healing in mice lacking the 5-lipoxygenase gene.Neuromodulatory role of endogenous interleukin-1β in acute seizures: possible contribution of cyclooxygenase-2Prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition.Nature of extracellular signal that triggers RhoA/ROCK activation for the basal internal anal sphincter tone in humans.PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model.COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice.COX-1 vs. COX-2 as a determinant of basal tone in the internal anal sphincter.Arachidonic acid metabolites follow the preferential course of cyclooxygenase pathway for the basal tone in the internal anal sphincter.Molecular Mechanism for Various Pharmacological Activities of NSAIDSCyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain.Comparative effects of the ω3 polyunsaturated fatty acid derivatives resolvins E1 and D1 and protectin DX in models of inflammation and painSelective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.New dogmas or old?Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.On the functionalization of benzo[e][2,1]thiazine.Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivoPopulation pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.Prostaglandin H2 synthase-1 and -2 expression in guinea pig gestational tissues during late pregnancy and parturition.
P2860
Q24675327-5B72A7C8-4A32-4182-BC0D-C0124DBCC778Q24792228-E836097D-5F40-44F8-A97B-46DFB2274D0BQ26779952-EE32A2D0-2E6C-47F7-A261-DD2CA87C34BCQ26827095-2637177D-0B3D-4C51-8364-CD8EF1B76BD7Q28186050-82618654-1A51-4BE2-90F7-36C6657463C2Q28191533-60EE6637-F8D7-40F7-A2BA-0A6B3ED99D89Q28344403-812EC93C-73C6-47B5-B18E-74533177FA2AQ28361239-34E7EDB3-2224-4E73-9EC8-1DD7E4EF5AFFQ28538492-CF5D9BF7-2F2B-477C-9127-ED6747F4F3FDQ33893991-598A5CDA-F2E8-4E53-9373-2AD8F8564189Q33939839-8F4AAC9C-121B-4F4D-93E1-FA97AAAD5DEEQ34134282-494FCF44-320D-43D5-9278-2A3A80A9DDDFQ34340684-47A1D0E4-E1F5-4A19-922C-D1D36F8541BFQ34806489-2DFC8988-2F55-46FC-AD2B-316CF6DBC14DQ34854231-519F7054-F83E-4904-B980-3D8C04739E0FQ35017693-644594C5-FA30-4732-B17A-ACDB3CAD8BC1Q35025067-3238206D-59BF-4410-B841-7CFF1D0FFED5Q35044089-AF27FA9B-44B0-4AAD-8C60-6882FE41F4B5Q35048654-DBF9FB84-88EC-4C6D-9EAA-DF5ADDF65699Q35129581-C0DCD4C7-44DE-4DBD-A68D-AD812D847F94Q35361527-B87DD8BD-BEA8-431A-B2F8-64C9B0F8E157Q35550092-7B9F9AEF-3EDC-4AC8-9B3D-5F3991CA7F5DQ35574583-E4973C85-DE58-4347-9478-7CD6765EDED6Q35654607-A44A9346-CAC9-481A-B449-DC40B5519EB3Q35671822-53267EFA-19D3-4A00-97B2-824B70F5C00EQ36834358-AFB0F433-BFF2-4E73-928C-F0E926CBAEAEQ37042403-207B3FB5-C5A3-4CC0-93C3-2A5A33659C42Q37073724-A46BD7D1-2B2D-40D2-9AC0-0CB25032C853Q37100255-C8F166AC-D4DE-4831-91C3-0A8B8629E23AQ37162481-B07DB8E9-8219-4C3B-A3F6-9269AD28E884Q38974315-FE6D9849-E0EA-464A-BF4D-B4E99F940558Q39499131-404CF005-3BFB-480D-85CF-99534B487F9CQ41634021-CEB5434F-0907-4104-B46E-EEAD0397E691Q41866780-453C30FF-075D-4A6D-B0DE-D88AF3EAA931Q41903025-F00B99A3-1374-4162-828A-0991930FF71EQ42010481-399F6D07-E518-4B20-91FB-2C350BCFE655Q42137850-2B143290-B429-4E7A-A9C6-31AB2E15ACF6Q42407745-E90A5CE3-51C0-4CC7-B4A5-17C99194954AQ43075810-836223F4-D3DB-426C-9F71-37CF9726DDBDQ46570987-BCE984E0-59D8-4365-AA4C-CAC5E2A0138C
P2860
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Rofecoxib [Vioxx, MK-0966; 4-( ...... ical and biochemical profiles.
@en
type
label
Rofecoxib [Vioxx, MK-0966; 4-( ...... ical and biochemical profiles.
@en
prefLabel
Rofecoxib [Vioxx, MK-0966; 4-( ...... ical and biochemical profiles.
@en
P2093
P1476
Rofecoxib [Vioxx, MK-0966; 4-( ...... ical and biochemical profiles.
@en
P2093
Charleson S
Cromlish W
Ford-Hutchinson AW
Forrest MJ
Gauthier JY
P304
P407
P577
1999-08-01T00:00:00Z